AtlasMark Financial’s Biogen BIIB Stock Holding History

AtlasMark Financial’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,222	Closed	-$285K	–	35
2019 Q3	$285K	Buy	+1,222	New	+$285K	0.71%	30

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AtlasMark Financial's BIIB Position: Q4 2019 in Review

AtlasMark Financial sold out of Biogen (BIIB) in Q4 2019, closing a stake of 1,222 shares — an estimated $285K sold.

AtlasMark Financial first reported a position in BIIB in Q3 2019 and held it in 1 quarter. The position peaked at $285K in Q3 2019. 1,103 funds tracked by Wall St. Rank hold BIIB as of Q4 2019.

AtlasMark Financial reported no remaining Biogen position as of Q4 2019 after selling out during the quarter.
AtlasMark Financial sold 1,222 Biogen shares in Q4 2019, an estimated $285K.
AtlasMark Financial first reported a position in Biogen in Q3 2019 and held it in 1 quarter.
AtlasMark Financial's Biogen position peaked at $285K in Q3 2019.
1,103 funds tracked by Wall St. Rank held Biogen as of Q4 2019.

Based on AtlasMark Financial's 13F filing for Q4 2019, filed 22 Apr 2026.